Olmesartan Medoxomil Mcdermott Laboratories

Olmesartan Medoxomil, the active ingredient in Olmesartan Medoxomil Mcdermott Laboratories, is an Angiotensin II receptor blocker (ARB) presented as an oral dosage form for oral use. It treats hypertension in adult patients. GNH USA supplies Olmesartan Medoxomil Mcdermott Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxomil is an ARB used to manage elevated blood pressure within the hypertension disease family.

Essential hypertension: lowers systolic and diastolic pressure to target levels. Isolated systolic hypertension: reduces high systolic readings, especially in older adults. Controlled hypertension (as part of combination therapy): helps achieve blood pressure goals when used with other antihypertensives.

Olmesartan Medoxomil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nausea - Back pain - Diarrhoea

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Acute renal impairment - Hyperkalaemia (elevated potassium) - Severe hypotension - Liver enzyme elevations - Myocardial infarction (rare)

When prescribing Olmesartan Medoxomil, clinicians should consider several safety measures. - Renal function monitoring: assess serum creatinine and eGFR periodically. - Serum potassium monitoring: avoid hyperkalaemia, especially with potassium‑sparing agents. - Hepatic impairment: use with caution in patients with liver disease. - Hypersensitivity: discontinue if signs of angioedema or rash appear. - Concomitant aliskiren in diabetes: avoid due to increased renal risk. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Olmesartan Medoxomil can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal dysfunction. - Dual therapy with ACE inhibitors: heightened risk of angioedema and renal impairment. - Potassium‑sparing diuretics (e.g., spironolactone): may cause severe hyperkalaemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Lithium: can raise lithium serum levels, risking toxicity. - Loop or thiazide diuretics: may enhance hypotensive response. - CYP450 inhibitors (e.g., ketoconazole): modest increase in plasma concentrations.